Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GS-0321 · COM503

Monoclonal antibody · Immune activation, directed at interleukin-18-binding protein (IL18BP) · developed by Compugen

Phase 1 Most advanced trial
CGEN Developer
1 Registered trials

What is GS-0321?

GS-0321 is a humanized IgG4 monoclonal antibody that binds interleukin-18-binding protein (IL18BP), releasing IL-18 from its complex with IL18BP. Freed IL-18 activates the IL-18 receptor on T cells and natural killer cells, inducing interferon-gamma secretion. It is studied in cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
COM503
Drug type
Monoclonal antibody
Targets
interleukin-18-binding protein (IL18BP)
Mechanism
Immune activation, directed at interleukin-18-binding protein (IL18BP)
Pathways
IL-18 signaling, T-cell and NK cell activation, interferon-gamma secretion
Therapy area
Oncology
Developer
Compugen Ltd (CGEN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06759649 Phase 1 Neoplasm Recruiting CGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cancer, Malignant TumorsNeoplasm

More from Compugen

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEN page.

Follow CGEN, the company behind GS-0321

See CGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.